Our Story
Since our inception in 2015 in Denmark, Liva has been leading the way in the field of digital therapeutics. Our ambition is to prevent, manage and treat chronic disease through behaviour and lifestyle change, with a keen focus on cardiometabolic conditions. Over the years, we have expanded our reach across national healthcare systems and geographies, marking our presence as a global force for advancing health outcomes.
We integrate seamlessly into healthcare systems offering a unique hybrid digital therapeutics platform that combines personalised, one-on-one lifestyle coaching with innovative digital-first delivery.
Our team of dedicated healthcare professionals create tailored behaviour and lifestyle change programs to support patients in their journey to prevent, manage and treat obesity, type 2 diabetes, pre-diabetes and other cardiometabolic conditions. The safety and efficacy of our digital therapeutic programmes are well-supported by extensive evidence from randomised controlled trials (RCTs) and other clinical studies.
Headquartered in Copenhagen and London, Liva is at the forefront of delivering industry-leading lifestyle change and chronic disease management programmes across Europe. Our collaborations with healthcare systems, including the NHS, as well as partnerships with some of the world’s largest life science companies and health insurers allow us to impact lives on a large scale.
Executive Management
![](https://livahealthcare.com/wp-content/uploads/2022/10/Shahram_BW_TemporaryImage.png)
Shahram Sharif
CEO
![Martin profilbillede](https://livahealthcare.com/wp-content/uploads/2022/05/Martin_1-2.webp)
Martin Paarse
COO & Deputy CEO
![Karen O'Regan](https://livahealthcare.com/wp-content/uploads/1540753110847-1-1.png)
Karen O'Regan
CCO & UK GM
![Sian Jarvis](https://livahealthcare.com/wp-content/uploads/1638458129053-1-1.png)
Sian Jarvis
Senior Advisor,
Communications & Marketing
Founders & Board of Directors
![](https://livahealthcare.com/wp-content/uploads/michel2.png)
Michel Lussier
Chair
![Rune profilbilleder](https://livahealthcare.com/wp-content/uploads/2019/06/Rune-1.png)
Rune Bech
Co-Founder
![Carl profilbilleder](https://livahealthcare.com/wp-content/uploads/2019/06/carl.png)
Carl Brandt
Co-Founder, Medical Director
![Boris profilbillede](https://livahealthcare.com/wp-content/uploads/2019/07/boris.jpg)
Boris Bernstein
MIG, Munich
![Guido profilbillede](https://livahealthcare.com/wp-content/uploads/2019/07/guido.jpg)
Guido Hegener
DHV, Berlin
![Søren profilbillede](https://livahealthcare.com/wp-content/uploads/2022/05/soren-2.webp)
Søren Hein
MIG, Munich
![](https://livahealthcare.com/wp-content/uploads/1516835627204.png)
Kristoffer Pedersen
Maj Invest, Copenhagen
Latest news
![](https://livahealthcare.com/wp-content/uploads/1717768991071.jpeg)
Rethinking Weight Management Approaches
The fight against obesity has long been a challenge, often marked by restrictive diets and a heavy emphasis on ‘willpower’. However, recent findings from the study “Early outcomes of referrals to the English National Health Service Digital Weight Management Programme”,
![](https://livahealthcare.com/wp-content/uploads/Ritzau-Image-960.jpg)
Liva wins Health Tech Hub Implementation Award 2024
At The Hermit award show, which took place on 7 May 2024, the Aalborg and Høje-Taastrup Municipalities together with Liva Healthcare were announced as winners
![Hope on the Horizon](https://livahealthcare.com/wp-content/uploads/Jeremy-Lapak-Unsplash-1024x576.gif)
Hope on the Horizon: Understanding Type 2 Diabetes Remission
by Dr Ellie Health, Medical Director @ Liva Healthcare Type 2 diabetes has reached epidemic proportions worldwide. According to the World Health Organisation (WHO), over
![Fitness runner with smartwatch](https://livahealthcare.com/wp-content/uploads/Fitness-runner-with-smartwatch-compress-1024x726.jpg)
Breakthrough Medications: Why Lifestyle Change Coaching is the Key to Success
Wegovy, the new weight-loss injection has become a household name. Worldwide demand for this new class of weight-loss medication known as GLP-1s containing semaglutide has